Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab.
University of South Florida, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Tampa, Florida 33606, USA. nbansal@health.usf.edu
Nisha
N
Bansal
Mitchell
M
Hoffman
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012422:Rupture, Spontaneous / Q000139:chemically induced; D001745:Urinary Bladder Diseases / Q000139:chemically induced* / Q000601:surgery
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab